jCyte Inc. Announces Promising Results In Retinitis Pigmentosa

jCyte Inc., a biotech company dedicated to preserving and restoring vision in patients with retinitis pigmentosa and other degenerative retinal disorders, announced today promising results from a Phase 2b clinical trial of jCell in retinitis pigmentosa (RP), an inherited retinal disease, irrespective of genetic subtype.

jCell is a first-in-class investigational treatment for RP which has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation. In addition to RMAT, jCell has received Orphan Drug designation from the FDA and the European Medicines Agency (EMA).